iTeos Therapeutics, Inc.
NASDAQ: ITOS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michel Detheux
- Employees
- 173
- Headquarters
- Watertown, United States
- IPO year
- 2020
- Market cap
- $448.7M
- Website
- https://www.iteostherapeutics.com
Loading ITOS…
Loading profile data…Frequently asked questions about ITOS
What does iTeos Therapeutics, Inc. (ITOS) do?
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase...
Where does ITOS trade?
iTeos Therapeutics, Inc. (ITOS) trades on the NASDAQ Global Market.
What sector is ITOS in?
iTeos Therapeutics, Inc. (ITOS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of iTeos Therapeutics, Inc.?
Michel Detheux is the chief executive officer of iTeos Therapeutics, Inc. (ITOS).
Where is iTeos Therapeutics, Inc. headquartered?
iTeos Therapeutics, Inc. is headquartered in United States.
Does ITOS pay a dividend?
iTeos Therapeutics, Inc. (ITOS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ITOS go public?
iTeos Therapeutics, Inc. (ITOS) completed its initial public offering in 2020.